QUATRO: Qualitative Analysis of Interviews Between Pharmacist and Elderly Patients Treated With Antithrombotics for an Ischemic Stroke.

Sponsor
Hospices Civils de Lyon (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05741593
Collaborator
(none)
30
1
12
2.5

Study Details

Study Description

Brief Summary

Cerebrovascular accident is the 2nd leading cause of death and the leading cause of disability in the world. There are brakes and levers of medication adherence in the context of secondary prevention treatment in stroke.

Condition or Disease Intervention/Treatment Phase
  • Other: Analysis of the verbatim from the transcription of the recorded interviews.

Detailed Description

Cerebrovascular accident is the 2nd leading cause of death and the leading cause of disability in the world. The probability of stroke recurrence is high: about 25% the first year , and 30 to 40% in the 5 years following the stroke. Recurrent strokes are responsible for significant disability, institutionalization, major neurocognitive disorders, and death.

In order to reduce the risk of stroke recurrence, multiple secondary prevention strategies have demonstrated their effectiveness, such as the prescription of drugs (in particular statins and antithrombotics), the establishment of a balanced diet, the practice of an activity physical, or even tobacco addiction.

However, the effectiveness of these strategies is optimal if and only if patients adhere to them.

In addition, previous studies have focused on the brakes and levers of medication adherence in the context of secondary prevention treatment in stroke.

In elderly patients, other obstacles could have been identified by specific studies, such as cognitive, sensory, functional disorders or even isolation.

Study Design

Study Type:
Observational
Anticipated Enrollment :
30 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
Qualitative Analysis of Interviews Between Pharmacist and Elderly Patients Treated With Antithrombotics for an Ischemic Stroke.
Anticipated Study Start Date :
Apr 1, 2023
Anticipated Primary Completion Date :
Apr 1, 2024
Anticipated Study Completion Date :
Apr 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Patients having had a stroke

elderly patients previously treated with an antithrombotic and admitted to hospital for an ischemic stroke

Other: Analysis of the verbatim from the transcription of the recorded interviews.
recorded semi-structured interviews between the patients and the pharmacist

Outcome Measures

Primary Outcome Measures

  1. Analysis of the verbatim from the transcription of the recorded interviews. [one year]

    Describing the content of discussions, relating to antithrombotic treatment for secondary prevention, between elderly patients previously treated with antithrombotics and admitted to hospital for an ischemic stroke and a pharmacist

Secondary Outcome Measures

  1. Analysis of verbatim statements from the transcription of recorded interviews on patients' representations and beliefs regarding antithrombotics [15 to 60 minutes per patient]

    Exploring patients' representations and beliefs regarding antithrombotics before and after the onset of stroke or recurrence of stroke

  2. Analysis of verbatim statements from the transcription of recorded interviews on patients' medication adherence to antithrombotics [15 to 60 minutes per patient]

    Explore patients' medication adherence to antithrombotics before the onset of stroke or recurrence of stroke

  3. Analysis of verbatim statements from the transcription of recorded interviews on the impact of the occurrence of stroke or recurrence of stroke on medication adherence [15 to 60 minutes per patient]

    Explore the impact of stroke occurrence or stroke recurrence on patient medication adherence (including motivation, ambivalence, confidence in medication benefits)

  4. Analysis of verbatim statements from the transcription of recorded interviews on the obstacles and levers to medication adherence [15 to 60 minutes per patient]

    Identify the barriers and levers to drug adherence with antithrombotics

Eligibility Criteria

Criteria

Ages Eligible for Study:
65 Years to 100 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Patients aged 65 and over

  • Patients hospitalized for an ischemic stroke or a recurrence of ischemic stroke, already being treated with an antithrombotic treatment (antiplatelet agent or anticoagulant ) prior to the stroke

  • Patients living at home and with a plan to return home.

  • Patients who did not object to the study and who gave their consent for the recording of the interview

Exclusion Criteria:
  • Patients with cognitive disorders or stroke sequelae that do not allow a semi-directive interview to be carried out (at medical discretion).

  • Non-French speaking patients

Contacts and Locations

Locations

Site City State Country Postal Code
1 institute of aging - Hôpital des Charpennes Villeurbanne France 69100

Sponsors and Collaborators

  • Hospices Civils de Lyon

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Hospices Civils de Lyon
ClinicalTrials.gov Identifier:
NCT05741593
Other Study ID Numbers:
  • 69HCL22_1074
  • 2023-A00181-44
First Posted:
Feb 23, 2023
Last Update Posted:
Mar 1, 2023
Last Verified:
Feb 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Hospices Civils de Lyon
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 1, 2023